Li 2018.

Methods	Study design: Randomised clinical trial Study duration: January 2016 to December 2016 Duration of follow‐up: 1 month Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC; no serious hepatic disease; no history of liver resection Exclusion criteria: Be allergic to chemotherapeutic drugs or lipiodol oil Age (mean ± SD, range): TACE + RFA: 51.7 ± 1.1 years, 39‐67 years; TACE: 51.8 ± 1.2 years, 38‐69 years Male (n/total): TACE + RFA: 15/30; TACE alone: 14/30
Interventions	TACE + RFA group (n = 30): Chemotherapeutic drugs: mitomycin 5 mg and theprubicin 20 mg RFA: The interval between TACE and RFA was 2 weeks. CT‐guided RFA TACE group (n = 30): Chemotherapeutic drugs: mitomycin 5 mg and theprubicin 20 mg
Outcomes	Tumour response: measured by area of tumour; assessed at 1 month after treatment Immune function
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.